Translate Sign in JOIN

Kileken ole-MoiYoi

kolemoiy's Profile Image

About Kileken ole-MoiYoi
Kileken ole-MoiYoi joined Novartis in September 2011 as the Manager of Capacity Building with the Malaria Initiative. Prior to Novartis, he was a Case Writer with the Global Health Delivery Project at Harvard. He led health system research projects, wrote several case studies on malaria treatment and prevention, and founded the Malaria Treatment and Prevention Community on GHDonline.

He has also worked for TechnoServe, a Washington DC-based international agricultural development organization, as a volunteer business consultant in Nairobi, Kenya. Prior to Technoserve, he worked with Community Centered Conservation in the Comoros, integrating economic development with marine conservation activities. While double majoring at Brown University (BA Political Economy of Development, BA Human Biology), he wrote an honors thesis on integrating principles of sustainable economic development with the fight against malaria in sub-Saharan Africa, and co-founded EduVision, a Zurich-based e-learning organization that focused on incorporating innovative information communication technology with rural education in developing countries.

All contributions made by this author are his own and do not necessarily represent the views of his employer, Novartis.

Role(s) / Profession(s)

  • Manager (Site/Facility, Program, Project)
  • Researcher

Organization

  • Novartis
    Website: http://www.novartis.com/ Type: For-Profit Organization Country: Switzerland About: Novartis was created in 1996 through the merger of Ciba-Geigy and Sandoz. The global headquarters are located in Basel, Switzerland. The mission of Novartis is to discover, develop and successfully market innovative products to prevent and cure diseases, to ease suffering and to enhance the quality of life.

Language(s)

  • English
  • French
  • Swahili

Recent Contributions

  • activity_icon

    Kileken ole-MoiYoi replied to "Recommendations in Malaria Policy to the Obama Administration" in the Malaria Treatment & Prevention community.

    Thank you for sharing these malaria policy recommendations which were made to the Obama administration. Although significant progress has been made in some countries, access to ACTs remains unacceptably low in many malaria endemic regions, while resistance to artemisinin threatens to spread from the Cambodia-Thai border. Many of these challenges arise due to bottlenecks in the health system (workforce, supply chain, M&E, governance) and the health infrastructure (clinics, roads, hospitals, storage facilities). Are there specific ...

  • activity_icon

    Kileken ole-MoiYoi started a discussion "Traditional medicines for malaria" in the Malaria Treatment & Prevention community.

    One of the more controversial topics presented at the 5th MIM Conference in Nairobi was the utilization of traditional medicines to fight malaria. It was reported during the conference that roughly 80% of Africans use traditional medicines. Even if the actual number is half of this, there is a significant need to better understand, formalize and regulate the system. Several participants believed that natural medicines should feature more prominently in the global debate regarding effective ...

  • activity_icon

    Kileken ole-MoiYoi replied to "Supply chain improvements could decrease under 5 malaria mortality by 37%" in the Malaria Treatment & Prevention community.

    Two recent articles published in the Malaria Journal raised some concerns regarding access to artemisinin-based combination therapy (ACT) in the private sector in Tanzania. In 2007, Tanzania changed its first line treatment from sulphadoxine-pyrimethamine (SP) to artemether-lumefantrine (AL). The AL combination was made available in the public sector and selectively in the private sector and its introduction was preceded by a social marketing campaign. Between 2004 and 2008, there was a 22% increase in the ...

  • activity_icon

    Kileken ole-MoiYoi started a discussion "Artemisinin market (in)stability" in the Malaria Treatment & Prevention community.

    When ACTs were first introduced to the global malaria community in 2001, there was a perceived shortage of artemisinin, the key active pharmaceutical ingredient. This perceived shortage caused artemisinin’s market price to rapidly increase peaking at $1,200 per kilogram in 2006. The high market price incentivized many farmers (artemisinin is sourced from Artemisia annua which is grown mainly in China and Eastern Africa) and companies to make both short and long-term investments in the production ...

  • activity_icon

    Kileken ole-MoiYoi replied to "Rapid Diagnostic Tests for Malaria in an Endemic Area - Journal Watch" in the Malaria Treatment & Prevention community.

    There seems to be mixed findings on the treatment of RDT-negative patients: in some countries, health workers prescribe ACTs anyway (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914063/, http://malariajournal.com/content/9/1/209), while in others they prescribe antibiotics or antipyretics (http://www.ajtmh.org/cgi/content/abstract/83/6/1238). Although in a clinic setting it is clear that a patient with a negative RDT or microscopy result must be treated, at a policy level, who is responsible for ensuring that an individual’s non-malarious fever is appropriately diagnosed and treated? Is the "malaria community" ...

More »

Recent Recommendations

Joined

September 29, 2008

Contributions

25

Recommendations

6